Head-To-Head Review: TherapeuticsMD (TXMD) & The Competition

TherapeuticsMD (NASDAQ:TXMD) is one of 896 public companies in the “Pharmaceuticals” industry, but how does it compare to its peers? We will compare TherapeuticsMD to similar businesses based on the strength of its risk, valuation, profitability, dividends, analyst recommendations, earnings and institutional ownership.

Insider and Institutional Ownership

30.7% of TherapeuticsMD shares are owned by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 1.7% of TherapeuticsMD shares are owned by company insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares TherapeuticsMD and its peers top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
TherapeuticsMD	$3.27 million	-$570,000.00	87.00
TherapeuticsMD Competitors	$3.56 billion	$3.19 billion	555.10

TherapeuticsMD’s peers have higher revenue and earnings than TherapeuticsMD. TherapeuticsMD is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for TherapeuticsMD and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TherapeuticsMD	1	0	0	0	1.00
TherapeuticsMD Competitors	7798	13888	25778	1037	2.41

As a group, “Pharmaceuticals” companies have a potential upside of 25.65%. Given TherapeuticsMD’s peers stronger consensus rating and higher probable upside, analysts plainly believe TherapeuticsMD has less favorable growth aspects than its peers.

Profitability

This table compares TherapeuticsMD and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TherapeuticsMD	-6.64%	-1.09%	-0.78%
TherapeuticsMD Competitors	-2,380.38%	-217.94%	-15.54%

Risk and Volatility

TherapeuticsMD has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500. Comparatively, TherapeuticsMD’s peers have a beta of -3.71, indicating that their average share price is 471% less volatile than the S&P 500.

Summary

TherapeuticsMD peers beat TherapeuticsMD on 9 of the 13 factors compared.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.